Journal
FRONTIERS IN ENDOCRINOLOGY
Volume 13, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fendo.2022.829879
Keywords
COVID-19; selective estrogen receptor modulators; estrogen receptor; breast cancer; review
Categories
Funding
- National Natural Science Foundation of China [81973574, 82174082, 81860443]
- Natural Science Foundation of Guangxi [2019GXNSFFA245001]
Ask authors/readers for more resources
This study discusses the impact of coronavirus infection on breast cancer patients and the potential therapeutic strategy of selective estrogen receptor modulators (SERMs).
Owing to the ongoing coronavirus disease 2019 (COVID-19) pandemic, we need to pay a particular focus on the impact of coronavirus infection on breast cancer patients. Approximately 70% of breast cancer patients express estrogen receptor (ER), and intervention therapy for ER has been the primary treatment strategy to prevent the development and metastasis of breast cancer. Recent studies have suggested that selective estrogen receptor modulators (SERMs) are a potential therapeutic strategy for COVID-19. With its anti-ER and anti-viral combined functions, SERMs may be an effective treatment for COVID-19 in patients with breast cancer. In this review, we explore the latent effect of SERMs, especially tamoxifen, and the mechanism between ER and virus susceptibility.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available